CTPI-2 has been studied in 1 paper since 2026: none in people yet, 1 in cells; 1 in the past year. No study of it in people or animals has been published yet. The newest story, Nov 6, 2026: “Protein linked to bone-eroding cell formation in lab experiments”.
1 paper studies it3 findingsUpdated
1 new paper in 30 daysSee all 1 papers on CTPI-2
The findings reach cells, none yet in people. 1 lab.
None of its findings points the other way.
Studies of CTPI-2 measured 3 outcomes; the most studied are reactive oxygen species (1 study), oxidative phosphorylation (1) and osteoclastogenesis (1).
Reactive oxygen species
downin cells1
CTPI-2 decreases reactive oxygen species in cells (CIC inhibition).
“CIC inhibition increased GCL activity, intracellular GSH content, and the GSH/GSSG ratio, accompanied by reduced reactive oxygen species accumulation.”
CellsCIC inhibition
Protein linked to bone-eroding cell formation in lab experiments
Cell death and differentiation
Oxidative phosphorylation
downin cells1
CTPI-2 impairs oxidative phosphorylation in cells during osteoclastogenesis.
“but also disrupted core metabolic processes, including tricarboxylic acid cycle engagement, amino acid biosynthesis, and mitochondrial respiration.”
Cellsduring osteoclastogenesis
Protein linked to bone-eroding cell formation in lab experiments
Cell death and differentiation
osteoclastogenesis
downin cells1
CTPI-2 decreases osteoclastogenesis in cells.
“Pharmacologic inhibition of CIC with CTPI-2 not only suppressed osteoclastogenesis”
Cellsosteoclast-lineage cells
Protein linked to bone-eroding cell formation in lab experiments
Cell death and differentiation
Cell experiments linked the protein to energy production and antioxidant regulation, two processes coordinated as bone-eroding cells develop.Cell experiments linked the protein to energy production and antioxidant regulation, two processes coordinated as bone-eroding cells develop.